CELLIX BIO PRIVATE LIMITED Received a Patent for THE TREATMENT OF CANCER — research and evidence
Match record identities first
The parliamentary annex identifies Cellix Bio Private Limited, application 201817045551, patent 317959 and a cancer-treatment title. Those entries support a specific historical match. A separate Indian Patent Office journal publication for Cellix concerns a later application and should not be confused with the same grant. Multiple Cellix families use similar therapeutic terminology. Verification focus: Check each application number, priority and publication on the official patent register. Decision implication: Avoid mixing disclosures or legal status across different family members.
Publication, grant and applicant history
A reliable chronology records earliest priority, PCT relationships if applicable, Indian filing, publication, examination, grant and any later assignment. Company branding and subsidiary names may change over time; the legal entity shown in the application record controls the starting evidence. A parliamentary table establishes one historical event but not all later entries. Verification focus: Capture official publication and register extracts with retrieval dates for every chronological row. Decision implication: A verifiable timeline is a distinct research output, not a reconstructed narrative from secondary sites.
Primary evidence starting point: Indian Parliament historical granted patents annex (Cellix grant listing). Where a source is a registry gateway, it establishes the verification route, not a verified finding on a named patent.
What compound and treatment claims may cover
Pharmaceutical disclosures commonly distinguish specific compounds, salts, polymorphs, compositions and therapeutic methods. The presence of cancer in a title or abstract does not mean every oncology indication or drug formula is claimed. In India, claim form and statutory exclusions must be evaluated from the actual text. Verification focus: Extract independent claims and map chemical structures, compositions and proposed uses separately. Decision implication: Avoid turning a therapeutic title into a blanket claim of market exclusivity.
Prior art, novelty and experimental support
A novelty analysis needs the specific chemical entities, earlier priority publications, known structural analogues and any described test results. The patent specification may report assays or proposed mechanisms, but these are not clinical trial confirmation. An efficacy assertion must be attributed to the underlying experiment and its limitations. Verification focus: Compare the identified claim against dated primary patent documents and any cited scientific papers. Decision implication: Novelty and therapeutic effectiveness are separate questions requiring separate evidence.
Indian exclusions and examination
Indian section 3(d) and other provisions can matter to certain pharmaceutical claims, depending on subject matter and the full prosecution record. An examiner objection cannot be responsibly described from assumption alone. Any assertion that a particular argument succeeded must be supported by the examination report and written response. Verification focus: Request the examination and response file, then quote only verified grounds and outcomes. Decision implication: A document-level case analysis is stronger than speculation about how the office reached its result.
Present legal status is an open check
Current ownership, annuity payments, revocation proceedings and status of individual claims cannot be concluded from a 2019 grant listing. This draft intentionally does not call the patent active or enforceable. The same caution applies to foreign family members because jurisdictions can differ. Verification focus: Check the patent register and transaction history as of the review date. Decision implication: Keep any commercial or freedom-to-operate conclusion on hold pending current verification.
Useful outputs of a Cellix dossier
The proposed dossier should link primary record identifiers, claim text, therapeutic disclosures, prior-art citations, examination events and current status. It can also map related patents without assuming they cover the same compounds or share identical priority dates. Document the difference between evidence, interpretation and remaining legal uncertainty. Verification focus: Produce a one-page timeline and claim-to-evidence table before offering comparative conclusions. Decision implication: The work product is a research record, not a clinical or legal clearance opinion.
Worked research example (illustrative)
For the historical record, the parliamentary annex supplies a verifiable starting tuple: Cellix Bio Private Limited, application 201817045551, patent 317959 and the reported August 2019 grant date. The tuple should be preserved exactly in the source register and checked against a present official patent extract. A separate Cellix publication may involve overlapping cancer language while claiming different compounds, priority or formulations. The research must not merge them because two titles sound alike. This is especially important where the company has several international families in adjacent therapeutic areas.
Original evidence and comparison matrix
An original claim evidence matrix for a pharmaceutical patent should distinguish chemical structure, salt or polymorph, dosage form, therapeutic purpose, disclosed assays and specific independent claim boundaries. For each row, show the location in the authentic specification and classify supporting evidence as verified, inferred or missing. If experimental evidence reports an in-vitro response, do not translate it into proven patient benefit without clinical data. Patent publication does not constitute medicine approval, and grant status does not establish efficacy or safety for a treatment.
Counterevidence, limits and next research decision
The current legal-status inquiry is deliberately open. A 2019 public grant listing does not show whether renewals were subsequently paid, rights were transferred or challenges changed the claims. Until those checks are made, the article can accurately discuss the patent’s historical appearance and the technical diligence method, but not label it presently active. The next research steps are an official specification download, independent claim comparison, prosecution-file retrieval and fresh register status check. The final note should identify which conclusions are supported and which remain to be determined.
Research evidence-quality and publication controls
Evidence standard and reproducibility. Preserve the parliamentary grant tuple while verifying current register status, exact claims and later patent-family events. The primary documents should be identified by issuing institution, title or record number, and the date on which their contents were checked. Two apparently consistent secondary descriptions are not independent confirmation if they reproduce the same earlier article. Any comparison should use equivalent technical or legal units, and preserve adverse facts rather than selecting only supportive passages.
What would change this analysis? A similarly titled Cellix publication or outdated status record can produce an erroneous claim of coverage. This possibility should be recorded in a dedicated contrary-evidence column, together with the source needed to investigate it. When a claim depends on an unverified record, it must remain an explicit research hypothesis.
Decision use. A historical grant fact is reportable; present enforceability and therapeutic benefit require different evidence. Keep an audit trail connecting the source, the exact statement, the reader's decision and the remaining limitation. No generalized content strategy should obscure the independent user need of this protected URL.
Primary sources and verification boundaries
- Indian Parliament historical granted patents annex (Cellix grant listing)
- India Patent Office Journal Cellix application publication 202147000040
- IP India patent public search starting point
- Indian Patents Act, section 3, official source
Source limitation: This article uses primary legal, patent, classification or platform materials where available. A primary-source gateway is not proof of any named patent’s current grant, title, claim scope or enforceability. The original WordPress article is retained in an editorial archive, not treated as authority for unverified legal claims.
General research information; not a legal opinion, patent validity opinion, regulatory clearance, or guarantee. Read the disclaimer
References and primary sources
- WIPO — PCT Frequently Asked Questions, updated August 2026. Official PCT procedure guidance.
- WIPO — PCT Applicant’s Guide, effective 23 April 2026. Official PCT applicant guide.
General research only. Any current grant, claim, ownership, legal status or professional opinion requires verification of official records and the facts of the particular matter. Full disclaimer


How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting